In this paper, we consider the role of meta-analysis and 'prospective meta-analysis' studies in childhood acute lymphocytic leukemia (ALL). In this issue, Valsecchi and Masera [1] give a thoughtful discourse, generally favorable to this approach. This article presents the opposite point of view. The aims of our article are to present the implications in clinical, rather than biostatistical terms, and to provide an extensive literature review of the subject of meta-analysis.
Review
The subject of meta-analysis as a statistical methodology is still in its infancy relative to the field of statistics as a whole, as evidenced by the fact that term 'metaanalysis' was not even coined until 1976 [2] . In spite of this short history, many articles and numerous books have now been published on all aspects of the subject. Further, the number of overviews appearing in the literature continues to increase each year, in apparent disregard of any real or perceived controversy. Perhaps performing a meta-analysis is too easy with the potential for fame too enticing to be bothered with such details as 'is this meta-analysis appropriate?' As Ingram Olkin said, 'Doing a meta-analysis is easy. Doing one well is hard.' Meta-analysis has its detractors as well as adherents, and we will attempt to provide a summary of the literature which represents both views. As this is a non-technical paper, emphasis will be on reviews, critiques, and commentaries generally accessible to the lay-person. We leave the technical discussions of advancing methodologies to other more appropriate venues.
Two important workshops occurred in 1985, after which a spate of articles appeared. The first was convened in October in Versailles, France to address the subject of clinical trials meta-analysis. The objectives were to provide an overview of the methodology, to identify pitfalls, limitations, and difficulties, to identify the key steps in carrying out meta-analysis, and to propose further lines of methodological research. The end result of this panel discussion appears as an article in Controlled Clinical Trials [3] . This is a very complete outline with examples on the entire meta-analysis process. The second workshop was organized several months after the Versailles conference as a joint venture between the Clinical Trials Branch of the US National Heart, Lung and Blood Institute and the Biometric Research Branch of the National Cancer Institute titled 'Methodologic Issues in Overviews of Randomized Clinical Trials'. The entire proceedings was published in Statistics in Medicine, Volume 6, and contains original works as well as discussions which demonstrate opposing points of view. Of particular note are the presentations by Peto [4] , Chalmers [5] , and Simon [6] . Richard Peto, who is probably the most prolific proponent of meta-analysis as a member of the Oxford group, argues that overviews are needed and that they give us 'the big picture'. Chalmers looks at meta-analysis as a discipline and warns us to be wary of potential bias. He also compares overviews to conducting large multi-center cooperative trials. Simon considers the application of meta-analysis to cancer clinical trials. He notes that in cancer therapeutics where there are many treatment variants, the dose intensity may be of crucial importance to effectiveness, and the population of patients with a given tumor type is very heterogeneous, overviews may only answer the following question: 'What is the average effect of a broad class of treatments on a broad class of patients?' Simon also warns that a cancer therapy may have a negligible positive effect on survival for one major subset of patients but a meaningful positive effect for another subset These, he points out, are not 'qualitative interactions' but they are differences which should influence therapeutic decision-making.
Bulpitt [7] writes concisely why, when and how meta-analyses should be performed, and L'Abbe et al. [8] and Sacks et al. [9] , provide the general principles involved in meta-analysis, especially in the clinical trial setting. Chalmers [10] and Mosteller et al. [11] describe some problems that arise in the context of meta-analysis, as well as some recent progress. Wachter [12] , Thompson et al. [13] , Goodman [14] , and Mann [15, 16] all present commentaries on the disparate opinions surrounding meta-analysis. As an example, Mann [15] states that while Peto and his group have clearly advocated meta-analysis, producing the most significant overviews in the medical literature, he also states that some say Peto has exaggerated his claims for metaanalysis and unfairly minimized its problems. For further reading, we have cataloged an extensive list of references on this important and controversial subject.
Meta-analysis
The basic idea behind meta-analysis is to combine the data from independently conducted randomized controlled trials (RCTs) to form an overall assessment of therapy. It is generally accepted that the effect sizes of the individual study questions must be either (a) identical (fixed effects) or (b) a conceptual random sample of interventions from a hypothetical target population of similar interventions (random effects). If properly planned, collaborative studies could be done as fixed effects, but in that scenario, we shall argue for a single multi-group trial. Retrospectively, all meta-analyses would have to be based on random effects. Unfortunately, there is so much diversity in past childhood trials, that this type of analysis breaks down for ALL. For example, the Childhood ALL Collaborative Group [126] conducted retrospective meta-analysis for a series of trials involving duration of therapy. Basically, they estimated an average effect size, taken over a number of studies where therapy was randomized to stop or continue after various lengths of time. The nature of the added therapy also varied. The question they sought to answer was whether or not the 'average' effect size of the target population of such interventions is greater than or less than zero. While such analysis might detect a significant effect when each of the trials have non-significant differences but with a general trend, they may downplay one or two breakthroughs which are at odds with the other trials [6] . As in any population, it is dangerous to generalize a population result to a specific member of that population, based solely on the population mean. When the take-home message is that increased duration of therapy is beneficial on average, it says nothing about a specific therapy being efficacious. If the individual RCT was inconclusive, one should not automatically utilize the longer therapy in the successor trial. The key to successful meta-analysis is the presumption of no qualitative interaction, namely that the effect size cannot have mixed behavior of being positive in some scenarios and negative in others. If this was the case, then a positive mean would imply positivity to each member of the target population of treatments. However, to be plausible, considerable homogeneity of the trials is required. In our opinion, the duration of therapy trials were far too diverse to accept this notion. The Childhood ALL Collaborative Group [126] estimated an overall effect for the question, but the validity of this estimate and its sampling properties are open to serious statistical questions. A fixed effect interpretation would require that the true target effect sizes of each individual RCT were equal. Although the test for homogeneity could not reject this hypothesis, it is generally wrong to equate lack of significance with no difference, unless the confidence intervals for the difference are uniformly tightly bound about the pooled estimate of effect size. The random effects interpretation is especially problematic as the random sampling assumption, that the RCT questions were selected independently from a target population of related study questions, cannot be justified. The RCTs represent series of trials from several groups, who exchange information with each other. The results of one trial will impact on the decision as to whether or not to conduct the next one. Effect sizes within a given group may have more in common than effect sizes from two different groups, due to the patient populations or the concomitant treatment. For example, had an early analysis of BFM 81 shown a benefit for longer treatment, the randomization of BFM 83 would have been terminated early. This type of correlation will lead to an overrepresentation of large numbers of RCTs with modest effects. Ignoring this correlation, as done in random effects analysis, could lead to a bias in the interpretation of the results.
As a simple and artificial example, suppose that we conduct a sequence of up to three studies, where we will stop and declare significance if and only if one of the trials is significant at the 0.017 level, carefully preserving the overall 0.05 level. At a later point, after the trials are completed, another researcher puts these trials together as a meta-analysis. Clearly the metaanalysis will inflate the overall type I error of the series of trials. The data are being used for a purpose which is both redundant, and not designed for in the individual trials. The question gets an extra unplanned chance to produce a positive result
Prospective meta-analysis trials
The basic idea of a prospective meta-analysis study, as opposed to an international intergroup study, is to decentralize the data collection. Each group would independently conduct RCTs of the same question, and the data would be pooled for a meta-analysis at the end of the RCTs. While this has some appeal in that international regulations can be circumvented, and that each group can use its own forms and data management centers, one needs to recognize the potential pitfalls. It is critical to have a single statistical office in charge of the study, and to insure it has accurate and timely data on toxicity and outcome. While this is feasible through decentralized data collection with rapid transmittal to a single central office, this would change the nature of the trial from a prospective meta-analysis to a true intergroup trial with decentralized data collection. The analysis would be no different! However, we make an important distinction with Valsecchi and Masera [1] when it comes to the scope of international involvement vs. single group involvement in ALL research. In the Pediatric Oncology Group, for example, we have three categories of risk for B-precursor ALL, defined by cytogenetics and the National Cancer Institute Consensus Risk Grouping [127] , covering the overwhelming majority of B-precursor ALL patients. We believe that one of these groups, accruing about 115 patients per year, will no longer need study, having a five year EFS of well over 90%. For the standard risk patients, we accrue about 340 patients per year and are planning for a 6% improvement from 78% EFS at four years, with an accrual duration of four years at 80% power and P< 0.05. In the high-risk group, we accrue about 175 patients per year and are planning for a 9% improvement from 60% at four years. These differences are plausible in a single group setting, even with multiple studies open.
Since plateaus in ALL occur beyond five years, one would gain little if one would put the worldwide resources together to complete accrual in a single year, rather than conducting several four year accrual intragroup studies. The potential for disaster would be far greater in the international scenario, as the rapid accrual and uniformity of patients in their follow-up would make safety monitoring for outcome and toxicity virtually impossible. Failures during the first year are rare, even in high risk ALL.
Another important downside to international studies in standard risk ALL is the reduction in the number of questions that can be asked. It takes about twice as many patients to look for a 5% difference as it does to look for a 7% difference. It seems advantageous to ask two questions less precisely. Studies with short accrual and long follow-up are not very useful in planning the next study, as the data will be too immature for use in planning. Hence, for standard risk ALL, current practice seems appropriate. For similar reasons, current practice seems appropriate for the majority of high-risk patients.
Nonetheless, we should not totally reject the international study ideas of Valsecchi et al. [1] out of hand. There may be situations where international collaboration is needed. One question might center on CNS prophylaxis in some higher-risk ALL patients, including T-cell. Can cranial irradiation (CXRT) be safely replaced by IT medication, without substantive loss in CNS protection? Since the CNS relapse rate in these patients is expected to be well under 10% at five years, a very large study, with thousands of patients would be required. This would not prevent individual study groups from conducting their own RCTs asking a systemic control question. The CXRT question could be part of a 2 x 2 factorial design in each group. The analysis of the CNS question would stratify by group and systemic control regimen within group. Further, there are rare high-risk subgroups for which randomized studies are only feasible in a multi-group setting. These include Philadelphia Chromosome Positive ALL, Infant ALL (eligibility restricted to under 12 months of age at diagnosis), or non-infant ALL with the 4-11 translocation. These studies need to be as rigorous as any intra-group trial, with a data monitoring committee, unified quality assurance, and uniform eligibility criteria. We recommend that data requirements be made as simple as possible, with data collection limited to those variables needed to achieve the study objectives, including the assessment of quality assurance and of side effects. A mechanism for institutional audits should be part of any such study plan.
International collaboration is also important to define common risk groups, which depend on state of the art biologic prognostic features. These should be prospective, so that a battery of such variables is collected across all groups, and that a quality control mechanism is in place to assure comparable data. These studies require far more patients than the individual RCTs, because of the multivariate nature of the analysis. At a minimum, the battery should include age, gender, white blood cell count, extramedullary disease, blast information at diagnosis (marrow and CSF), early responsiveness to induction therapy (marrow and blood), detailed immunophenotying data, and the full cytogenetics clone. The definition of this battery is expected to change over generations of protocols as new features emerge and outcome improves.
